Cardiovascular disease risk in an aging HIV population: Not just a question of biology

Current Opinion in HIV and AIDS

Volumn 9, Issue 4, 2014, Pages 346-354

  So Armah, Kaku ^a   Freiberg, Matthew S ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; clinical guidelines; healthcare disparities; HIV; multimorbidity; polypharmacy

Indexed keywords

ANTIRETROVIRUS AGENT;

AGING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; HEALTH CARE DISPARITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; CARDIOVASCULAR DISEASES; COMPLICATION; HIV INFECTIONS; HUMAN;

AGING; CARDIOVASCULAR DISEASES; COMORBIDITY; HIV INFECTIONS; HUMANS;

EID: 84902244089     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000065     Document Type: Review

References (114)

1. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4 counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007; 44:179-187.
2. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-1139.
3. Grinsztejn B, Luz PM, Pacheco AG, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One 2013; 8:e59768.
4. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
5. Ehren K, Hertenstein C, Kummerle T, et al. Causes of death in HIV-infected patients from the Cologne-Bonn cohort. Infection 2014; 42:135-140.
6. Aldaz P, Moreno-Iribas C, Egues N, et al. Mortality by causes in HIV-infected adults: comparison with the general population. BMC Public Health 2011; 11:300.
7. Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
8. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Internal Med 2013; 173:614-622.
9. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012; 13:453-468.
10. Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011; 6:266-271.
11. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
12. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
13. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIVinfected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-1631.
14. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med 2011; 171:737-743.
15. Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US healthcare system. J Acquir Immune Defic Syndr 2012; 60:351-358.
16. Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012; 59:1891-1896.
17. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
18. Group DADS, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
19. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
20. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr 2014; 65:160-166.
21. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a 'virtual' cohort using the National VA Health Information System. Med Care 2006; 44 (8 Suppl 2):S25-30.
22. Hulten E, Mitchell J, Scally J, et al. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart 2009; 95:1826-1835.
23. Monroe AK, Dobs AS, Xu X, et al. Low free testosterone in HIV-infected men is not associated with subclinical cardiovascular disease. HIV Med 2012; 13:358-366.
24. Fitch KV, Looby SE, Rope A, et al. Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS 2013; 27:49-57.
25. Hsue PY, Scherzer R, Hunt PW, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc 2012.
26. Rose H, Low H, Dewar E, et al. The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study. Atherosclerosis 2013; 229:206-211.
27. Hileman CO, Longenecker CT, Carman TL, McComsey GA. C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy. J Acquir Immune Defic Syndr 2014; 65:340-344.
28. Hileman CO, Carman TL, Longenecker CT, et al. Rate and predictors of carotid artery intima media thickness progression in antiretroviral-naive HIVinfected and uninfected adults: a 48-week matched prospective cohort study. Antivir Ther 2013; 18:921-929.
29. Kelesidis T, Kendall MA, Yang OO, et al. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-1567.
30. Sainz T, Alvarez-Fuente M, Navarro ML, et al. Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study. J Acquir Immune Defic Syndr 2014; 65:42-49.
31. Desvarieux M, Boccara F, Meynard JL, et al. Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected neversmokers independent of antiretroviral therapy. AIDS 2013; 27:2603-2614.
32. Naylor K, Li G, Vallejo AN, et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174:7446-7452.
33. Plowden J, Renshaw-Hoelscher M, Engleman C, et al. Innate immunity in aging: impact on macrophage function. Aging cell 2004; 3:161-167.
34. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-212.
35. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
36. Tracy RP, Doyle MF, Olson NC, et al. T-helper type 1 bias in healthy people is associated with cytomegalovirus serology and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc 2013; 2:e000117.
37. Rogacev KS, Cremers B, Zawada AM, et al. CD14CD16 monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60:1512-1520.
38. Ammirati E, Cianflone D, Vecchio V, et al. Effector memory T cells are associated with atherosclerosis in humans and animal models. J Am Heart Assoc 2012; 1:27-41.
39. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205 (Suppl 3):S375-S382.
40. Pardali E, Waltenberger J. Monocyte function and trafficking in cardiovascular disease. Thromb Haemost 2012; 108:804-811.
41. Baker JV, Hullsiek KH, Singh A, et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS 2014; 28:831-840.
42. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012; 120:4599-4608.
43. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-1236.
44. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. J Am Med Assoc 2012; 308:379-386.
45. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409-2412.
46. Westhorpe CL, Maisa A, Spelman T, et al. Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. Immunol Cell Biol 2014; 92:133-138.
47. Sabin CA, Ryom L, De Wit S, et al. Associations between immune depression and cardiovascular events in HIV infection. AIDS 2013; 27:2735-2748.
48. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55:615-619.
49. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4 T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-447.
50. Longenecker CT, Funderburg NT, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14:385-390.
51. Merlini E, Luzi K, Suardi E, et al. T-cell phenotypes, apoptosis and inflammation in HIV patients on virologically effective cART with early atherosclerosis. PLoS One 2012; 7:e46073.
52. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203:452-463.
53. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011; 217:207-213.
54. Arildsen H, Sorensen KE, Ingerslev JM, et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14:1-9.
55. Krishnan S, Schouten JT, Atkinson B, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr 2012; 61:381-389.
56. Baker JV, Neuhaus J, Duprez D, et al. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 2012; 60:128-134.
57. Young B, Squires KE, Ross LL, et al. Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/ lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses 2013; 29:350-358.
58. Hileman CO, Wohl DA, Tisch DJ, et al. Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to nonabacavir-containing regimens. AIDS Res Hum Retroviruses 2012; 28:1561-1564.
59. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. J Am Med Assoc 2012; 308:387-402.
60. Lakey W, Yang LY, Yancy W, et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses 2013; 29:435-440.
61. Mata-Marin JA, Mendez-Cruz R, Arroyo-Anduiza CI, et al. Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naive infected patients. J Med Virol 2013; 85:1321-1326.
62. Overton ET, Arathoon E, Baraldi E, Tomaka F. Effect of darunavir on lipid profile in HIV-infected patients. HIV Clin Trials 2012; 13:256-270.
63. Gupta SK, Shen C, Moe SM, et al. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One 2012; 7:e45716.
64. Agarwal S, Busse PJ. Innate and adaptive immunosenescence. Ann Allergy Asthma Immunol 2010; 104:183-190. [quiz 90-2, 210]
65. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. J Am Med Assoc 2003; 289:2978-2982.
66. Kaplan RC, Landay AL, Hodis HN, et al. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012; 60:359-368.
67. Armah K, Lim J, Re VL, et al. Effect of HIV seroconversion and ART initiation on multiple biomarkers of organ function. Conference on Retroviruses and Opportunistic Infections, March 3-6, Atlanta, GA; 2013.
68. Pasternak AO, de Bruin M, Jurriaans S, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis 2012; 206:1443-1452.
69. Strain MC, Richman DD. New assays for monitoring residual HIV burden in effectively treated individuals. Curr Opin HIV AIDS 2013; 8:106-110.
70. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation and monocyte activation. Clin Infect Dis 2012; 55:126-136.
71. Althoff K, Wyatt C, Gibert C, et al. Cardiovascular disease and other non-AIDS events: epidemiology and pathogenesis. Conference on Retroviruses and Opportunistic Infections, March 3-6, Atlanta, GA; 2013.
72. Herrin M, Tate J, Freiberg M, et al. Risk of incident diabetes associated with weight gain after combination antiretroviral therapy (ART) initiation. Conference on Retroviruses and Opportunistic Infections, March 3-6, Atlanta, GA; 2013.
73. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45:1593-1601.
74. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011; 106:858-867.
75. Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49:225-232.
76. Roed T, Lebech AM, Kjaer A, Weis N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging 2012; 32:421-430.
77. Bedimo R, Westfall AO, Mugavero M, et al. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11:462-468.
78. Data Collection on Adverse Events of Anti HIVDSG. Weber R, Sabin C, Reiss P, et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010; 15:1077-1086.
79. Hechter RC, Budoff M, Hodis HN, et al. Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study. Atherosclerosis 2012; 223:433-436.
80. Parrinello CM, Sinclair E, Landay AL, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIVinfected women. J Infect Dis 2012; 205:1788-1796.
81. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275-2283.
82. D'Agostino RB Sr. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis 2012; 205 (Suppl 3):S362-S367.
83. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7:218-230.
84. Moreira Guimaraes MM, Bartolomeu Greco D, Ingles Garces AH, et al. Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract 2010; 64:739-745.
85. Edwards-Jackson N, Kerr S, Tieu H, et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med 2011; 12:510-515.
86. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabil 2010; 17:491-501.
87. Barros ZM, de Alencar Ximenes RA, Miranda-Filho DB, et al. Comparison between the Framingham and prospective cardiovascular of Munster scores for risk assessment of coronary heart disease in human immunodeficiency virus-positive patients in Pernambuco, Brazil. Metab Syndr Relat Disord 2010; 8:489-497.
88. Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 2013; 30:613-628.
89. Nachega JB, Hsu AJ, Uthman OA, et al. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 2012; 26 (Suppl 1):S39-53.
90. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012; 60 (Suppl 1):S1-18.
91. Holtzman C, Armon C, Tedaldi E, et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med 2013; 28:1302-1310.
92. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66:2107-2111.
93. Gedela K, Vibhuti M, Pozniak A, et al. Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection. HIV Med 2014; 15:257-268.
94. Maiese E,Malmenäs M, Atkinson M. Impact of comorbidities on HIVmedication persistence: a retrospective database study usingUSclaims data. International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland; 2012.
95. Barry DT, Goulet JL, Kerns RK, et al. Nonmedical use of prescription opioids and pain in veterans with and without HIV. Pain 2011; 152:1133-1138.
96. Green TC, Kershaw T, Lin H, et al. Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend 2010; 110:208-220.
97. Ettenhofer ML, Hinkin CH, Castellon SA, et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatric Psychiatry 2009; 17:281-290.
98. Crystal S, Akincigil A, SambamoorthiU, et al. The diverse older HIV-positive population: a national profile of economic circumstances, social support, and quality of life. J Acquir Immune Defic Syndr 2003; 33 (Suppl 2):S76-83.
99. Anema A, Weiser SD, Fernandes KA, et al. High prevalence of food insecurity among HIV-infected individuals receiving HAART in a resource-rich setting. AIDS Care 2011; 23:221-230.
100. Work Group for HIV, Aging Consensus P. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatrics Soc 2012; 60:974-979.
101. Gleason LJ, Luque AE, Shah K. Polypharmacy in the HIV-infected older adult population. Clin Interventions Aging 2013; 8:749-763.
102. Waters L, Patterson B, Scourfield A, et al. A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. Int J STD AIDS 2012; 23:546-552.
103. Hanlon JT, Weinberger M, SamsaGP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996; 100:428-437.
104. Action to Control Cardiovascular Risk in Diabetes Study G. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
105. Group AS, Cushman WC, Evans GW, et al. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
106. Burkholder GA, Tamhane AR, Salinas JL, et al. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis 2012; 55:1550-1557.
107. Suchindran S, Regan S, Meigs JB, et al. Comparison of aspirin use and incident myocardial infarction rates in HIV and HIV-patients in a large US healthcare system. Conference on Retroviruses and Opportunistic Infections, March 3-6, Atlanta, Georgia; 2013.
108. Pearce D, Ani C, Espinosa-Silva Y, et al. Comparison of in-hospital mortality from acute myocardial infarction in HIV sero-positive versus sero-negative individuals. Am J Cardiol 2012; 110:1078-1084.
109. Guaraldi G, Zona S, Menozzi M, et al. Cost of noninfectious comorbidities in patients with HIV. ClinicoEcon Outcomes Res 2013; 5:481-488.
110. Masica AL, Richter KM, Convery P, Haydar Z. Linking joint commission inpatient core measures and national patient safety goals with evidence. Proc (Bayl Univ Med Cent) 2009; 22:103-111.
111. Redberg RF, Benjamin EJ, Bittner V, et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol 2009; 54:1364-1405.
112. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J Am Coll Cardiol 2008; 52:2046-2099.
113. Guaraldi G, Zona S, Alexopoulos N, et al. Coronary aging in HIV-infected patients. Clin Infect Dis 2009; 49:1756-1762.
114. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2013.